已收盤 11-20 16:00:00 美东时间
+0.015
+1.34%
11月18日,Nkarta(NKTX)收涨3.31%,报1.25美元,成交额128.44万美元,市值8953.1万美元。 行情数据 • 开盘价:1.22美元 ...
11-18 08:04
Nkarta Inc. (NASDAQ:NKTX) announced Wednesday that its experimental NKX019 cell therapy showed encouraging initial safety results in 40 patients across five autoimmune diseases. The company presented the findings at the American College of Rheumatology’s ACR Convergence 2026 conference in Orlando. T...
11-11 23:44
11月11日,Nkarta(NKTX)收跌15.09%,报1.35美元,成交额167.49万美元,市值9669.31万美元。 行情数据 • 开盘价:1.53美元...
11-11 08:01
今日重点评级关注:摩根士丹利:维持Riot Platforms"超配"评级,目标价从35.5美元升至41美元;Canaccord Genuity:维持塞德斯医疗"买入"评级,目标价从60美元升至68美元
11-10 18:30
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
11-10 00:58
Nkarta ( ($NKTX) ) has shared an update. On November 9, 2026, Nkarta announced ...
11-09 22:48
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 55.17 percent decrease over losses of $(0.29) per share from the same period last year.
11-06 05:53
Nkarta reported its third-quarter 2026 financial results, highlighting $216 million in cash reserves and plans to present initial clinical data for NKX019 in myositis and systemic sclerosis at ACR Convergence 2026. The company expects its cash to fund operations into 2029. NKX019 clinical trials continue with outpatient dosing at community sites. R&D expenses were $29.5 million, G&A expenses $6.3 million, and net loss $33.3 million for the quarte...
11-05 21:34
11月4日,Nkarta(NKTX)收涨0.66%,报1.53美元,成交额115.65万美元,市值1.1亿美元。 行情数据 • 开盘价:1.54美元 • 最高价...
11-04 07:56
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从50美元升至51美元;HC Wainwright & Co.:上调伊诺维奥制药评级至"买入",目标价5美元
11-03 18:20